Clinical Trials Logo

Filter by:
NCT ID: NCT06467435 Not yet recruiting - Thyroid Eye Disease Clinical Trials

Evaluation of K9 in Subjects With Thyroid Eye Disease (TED)

Start date: July 2024
Phase: Phase 1
Study type: Interventional

The objective of this clinical trial is to evaluate the plasma pharmacokinetics of K9 in healthy subjects (Cohort 1) and the safety and treatment efficacy of K9 in patients with active Thyroid Eye Disease (Cohort 2). Participants will receive study medication one time or for up to 4 weeks. Participants will have blood drawn and/or complete eye exams and questionnaires. The planned duration of this study is 6 weeks.

NCT ID: NCT06467344 Recruiting - Stargardt Disease Clinical Trials

Study to Evaluate ACDN-01 in ABCA4-related Retinopathy (STELLAR)

STELLAR
Start date: June 29, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

This study is an open-label, single ascending dose clinical trial in participants who have ABCA4-related retinopathies. This is the first-in-human clinical trial in which ACDN-01 will be evaluated for safety, tolerability, and preliminary efficacy following a single subretinal injection of ACDN-01.

NCT ID: NCT06467305 Not yet recruiting - Speech Clinical Trials

Speech Motor Learning and Retention (Aim 1)

Start date: July 2024
Phase: N/A
Study type: Interventional

The overall goal of this research is to test a new model of speech motor learning, whose central hypothesis is that learning and retention are associated with plasticity not only in motor areas of the brain but in auditory and somatosensory regions as well. The strategy for the proposed research is to identify individual brain areas that contribute causally to retention by disrupting their activity with transcranial magnetic stimulation (TMS). Investigators will also use functional magnetic resonance imaging (fMRI) which will enable identification of circuit-level activity which predicts either learning or retention of new movements, and hence test the specific contributions of candidate sensory and motor zones. In other studies, investigators will record sensory and motor evoked potentials over the course of learning to determine the temporal order in which individual sensory and cortical motor regions contribute. The goal here is to identify brain areas in which learning-related plasticity occurs first and which among these areas predict subsequent learning.

NCT ID: NCT06467292 Not yet recruiting - Speech Clinical Trials

Speech Motor Learning and Retention (Master Protocol)

Start date: July 2024
Phase: N/A
Study type: Interventional

The overall goal of this research is to test a new model of speech motor learning, whose central hypothesis is that learning and retention are associated with plasticity not only in motor areas of the brain but in auditory and somatosensory regions as well.

NCT ID: NCT06467214 Not yet recruiting - Social Isolation Clinical Trials

Increasing Veterans' Social Engagement and Connectedness

CONNECTED
Start date: July 1, 2024
Phase: Early Phase 1
Study type: Interventional

Social isolation is a negative social determinant of health (SDoH) that affects 1-in-5 adults in the U.S. and 43% of Veterans. Social isolation is estimated to cost the nation $6.7 billion annually in federal healthcare spending. Yet, social isolation has rarely been the direct focus of healthcare interventions. The proposed project is a randomized controlled trial that seeks to test the effectiveness of the Increasing Veterans' Social Engagement and Connectedness (CONNECTED) intervention on social isolation among diverse Veteran groups in primary care clinics. CONNECTED involves three key services delivered by peers via telehealth through individual and group sessions over 8 weeks: 1) peer support, which includes person-centered assessment for social isolation, 2) psychosocial interventions to address social isolation, and 3) navigation (i.e., connecting Veterans to social resources). Findings from this study will contribute to the VA's efforts to address SDoH among Veterans and to provide high quality, person-centered, and equitable care to all Veterans.

NCT ID: NCT06467201 Not yet recruiting - Clinical trials for Healthy Postmenopausal Women

SAD Study to Evaluate Safety, Tolerability, and Pharmacokinetic Profile of KSHN001126 in Healthy Post-Menopausal Females

Start date: June 2024
Phase: Phase 1
Study type: Interventional

This is an Open-label, Sequential dosing, Single Ascending Dose (SAD) Study to Determine the Safety, Tolerability, and Pharmacokinetic (PK) Profile of KSHN001126 in Healthy Human Post-Menopausal Female Volunteers. The primary objective of the study is to evaluate the safety and tolerability of increasing single doses of KSHN001126 while the secondary objective is to evaluate the plasma PK profile of KSHN001126 and its metabolites (KSHN001167, KSHN001168 and Fulvestrant) following ascending single oral doses of KSHN001126.

NCT ID: NCT06467136 Recruiting - Apraxia of Speech Clinical Trials

Motor Imagery for Treatment Enhancement and Efficacy in Persons With Apraxia of Speech

MI-TEE
Start date: December 11, 2023
Phase: N/A
Study type: Interventional

Treatment of post-stroke apraxia of speech (AOS) requires frequent and ongoing practice with a speech-language pathologist to facilitate lasting behavioral change, which is costly and, therefore, inaccessible to many patients. Thus, there is a critical need to identify novel, cost-effective ways to supplement speech therapy to increase opportunities for practice and optimize treatment outcomes. Our long-term goal is to develop an effective, home-practice, computer-based, motor imagery protocol Motor Imagery for Treatment Enhancement and Efficacy (MI-TEE) which will serve as an adjunct to routine speech therapy to optimize treatment response in persons with AOS. The overall objectives of this application are to (i) evaluate the acceptability and feasibility of MI-TEE as a home practice program and (ii) determine the efficacy of MI-TEE with speech therapy, compared to speech therapy alone, in improving speech production in people with AOS. Our central hypothesis is that MI-TEE will be an accessible, feasible, and efficacious adjunct to speech therapy. To attain our objectives, the following specific aims will be pursued using two single-subject experimental designs with multiple baselines across participants (n=18): 1) Evaluate the acceptability and feasibility of MI-TEE as an adjunct to speech therapy for the rehabilitation of AOS; and 2) Compare the efficacy of adjunctive MI-TEE plus standard speech therapy to standard speech therapy alone. Under the first aim, observational data, surveys, and semi-structured interviews will be employed to assess the acceptability (perceived satisfaction, appropriateness, and intent to continue use) and feasibility (recruitment, retention, and intervention adherence rates) of MI-TEE. For the second aim, accuracy of articulation for trained words and untrained words (generalization) will be measured pre-treatment, repeatedly during the treatment phase, and post-treatment. Improvements in speech accuracy will be documented using a binary scoring system (correct/incorrect). Multilevel analyses will be used to address rate of acquisition, overall change, and response variation across participants.

NCT ID: NCT06466941 Not yet recruiting - Opioid Use Clinical Trials

Understanding the Acute Pain Phenotype in Patients Undergoing Surgery

Start date: July 1, 2024
Phase:
Study type: Observational

The goal of this observational study is to learn about how regional anesthesia (numbing medication) affects pain in patients with different psychosocial phenotypes such as different levels of concern about pain, sleep issues, and anxiety, who are having surgery. The main questions are: 1. Do psychosocial factors such as concerns about pain, sleep, anxiety affect the effectiveness of regional anesthesia? 2. Do psychosocial factors and regional anesthesia affect the amount of opioids used after surgery? 3. Do psychosocial factors and regional anesthesia affect development of chronic postsurgical pain?

NCT ID: NCT06466876 Recruiting - Clinical trials for Autism Spectrum Disorder

Word Learning in Autistic Children

Start date: July 28, 2023
Phase: Early Phase 1
Study type: Interventional

Children on the autism spectrum sometimes have difficulty learning new words and using the newly taught information in different situations. In this study, we are testing whether strategies that have been found to improve word learning in non-autistic children will also help autistic children. Specifically, we aim to test whether autistic children learn words more successfully if we teach the words by repeating the words to the child (re-study) or if we teach the words by first labeling each word and then quizzing the child (repeated quizzing). The main questions it aims to answer are: - When teaching nouns (names of exotic animals), is learning stronger if autistic children re-study or engage in repeated quizzing of the newly taught words? - When teaching adjectives (visible features of objects, like a bumpy chair), is learning stronger if autistic children re-study or engage in repeated quizzing of the newly taught adjectives? - Does the word learning condition (re-study vs. repeated quizzing) impact whether autistic children are more successful in demonstrating their knowledge of the newly taught words in different contexts? - Are autistic features related to patterns of word learning? Participants will: - Learn new words with half of the words being taught in one way (re-study) and the other half of the words being taught in the other way (repeated quizzing). - Participate in 5-minute and 1-week tests of the newly taught words to measure child learning. - Complete other language, thinking, and autism clinical assessments.

NCT ID: NCT06466798 Not yet recruiting - Clinical trials for Recurrent Medulloblastoma

Fourth Ventricular Administration of Immune Checkpoint Inhibitor (Nivolumab) and Methotrexate or 5-Azacytidine for Recurrent Medulloblastoma, Ependymoma, and Other CNS Malignancies

Start date: July 1, 2024
Phase: Phase 1
Study type: Interventional

The goal of this clinical trial is to assess the safety, toxicity, and antitumor activity of fourth ventricular infusions of nivolumab plus 5-azacytidine for recurrent ependymoma and nivolumab plus methotrexate for recurrent medulloblastoma and other CNS malignancies. Additionally, the study will explore immunologic responses to nivolumab. The hypothesis is that local administration of nivolumab, an immune checkpoint inhibitor, is safe and will lead to even more robust treatment responses when administered following 5-azacytidine in patients with recurrent ependymoma or methotrexate in patients with medulloblastoma or other CNS tumors.